Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus - 18/08/11
, Ming-Kuo Ting, MD a, Subodh Verma, MD, PhD, FACC b, Li-Tang Kuo, MD a, Ning-I Yang, MD a, I-Chang Hsieh, MD a, Shin-Yi Wang, BSc a, Agnes Hung, BSc a, Wen-Jin Cherng, MD, FACC aRésumé |
Background |
Endothelial progenitor cells (EPCs) are present in peripheral blood and can promote postnatal angiogenesis. The number and function of circulating EPCs are altered in diabetics. This study sought to investigate whether the number and functional properties of EPCs from patients with type II diabetes could be improved by pioglitazone.
Methods |
For this randomized controlled study, we recruited 36 type II diabetic patients on metformin monotherapy with a glycohemoglobin A1c of <7%. Patients were separated into pioglitazone (n = 24) and control (n = 12) groups. The number and functional activity of EPCs, and the brachial artery flow-mediated dilation were determined before and after pioglitazone treatment (8 weeks) as an add-on therapy to metformin. In addition, direct effects of pioglitazone on EPCs were also investigated.
Results |
After pioglitazone treatment, the numbers of circulating EPCs significantly increased (from 0.44% ± 0.14% to 0.89% ± 0.29%, P = .01). The migratory response and the adhesive capacity to fibronectin and collagen were improved by 158%, 34%, and 83%, respectively (all P < .05). Treatment with pioglitazone significantly lowered triglyceride, very low density lipoprotein cholesterol, and high-sensitivity C-reactive protein (hsCRP) levels, and increased high-density lipoprotein levels and insulin sensitivity (all P < .05). The increase in the number of circulating EPCs and the improvement in the migratory response after pioglitazone treatment were independently correlated to the decrease in hsCRP levels (P ≤ .01). The increase in the adhesive capacity was independently correlated to the decreases in very low density lipoprotein cholesterol (P = .01) and hsCRP levels (P = .03). In addition, pioglitazone was also demonstrated to have direct effects on increasing EPC proliferation and colony formation, and attenuating EPC apoptosis (all P < .05, versus the controls). There were no significant changes in flow-mediated dilation in either group.
Conclusions |
Pioglitazone significantly increased the number and improved the functional properties of EPCs in type II diabetic patients through direct effects and/or anti-inflammation and lipid modification effects.
Le texte complet de cet article est disponible en PDF.Plan
Vol 152 - N° 6
P. 1051.e1-1051.e8 - décembre 2006 Retour au numéro
Article précédent
- Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
- Harvey D. White, Neal S. Kleiman, Kenneth W. Mahaffey, Yuliya Lokhnygina, Karen S. Pieper, Karen Chiswell, Marc Cohen, Robert A. Harrington, Derek P. Chew, John L. Petersen, Lisa G. Berdan, Philip E.G. Aylward, Christopher C. Nessel, James J. Ferguson, Robert M. Califf
- Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial
- Stephen G. Ellis, Marc S. Penn, Brian Bolwell, Mario Garcia, Matthews Chacko, Thomas Wang, Kelly J. Brezina, Gerry McConnell, Eric J. Topol
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?